• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    3 Promising Penny Stocks With Market Caps Under $800M

    Simply Wall St·10/23/2026 11:05:00
    语音播报

    Over the last 7 days, the U.S. market has dropped 1.2%, but it remains up 11% over the past year with earnings forecasted to grow by 17% annually. In such a dynamic landscape, investors often look for stocks that combine affordability and growth potential, which is where penny stocks come into play. Although the term 'penny stocks' might seem outdated, these smaller or newer companies can still offer intriguing opportunities when backed by strong financials and solid business models.

    Let's review some notable picks from our screened stocks.

    SNDL (SNDL)

    Simply Wall St Financial Health Rating: ★★★★★★

    Overview: SNDL Inc. is involved in the production, distribution, and sale of cannabis products for the adult-use market in Canada and internationally, with a market cap of approximately $312.01 million.

    Operations: The company's revenue is derived from three main segments: Liquor Retail generating CA$527.02 million, Cannabis Retail contributing CA$328.85 million, and Cannabis Operations accounting for CA$136.17 million.

    Market Cap: $312.01M

    SNDL Inc., with a market cap of approximately $312.01 million, operates in the cannabis sector, generating significant revenue from liquor and cannabis retail. Despite being unprofitable, SNDL has reduced losses by 31.6% annually over five years and maintains a strong cash position with no debt, allowing for strategic growth opportunities. Recent activities include share buybacks totaling CA$43.1 million and strategic investments focused on expanding U.S. operations, particularly in Florida and Texas. Management changes have occurred with Carlo Cannell's resignation from the board as part of ongoing governance adjustments to support its growth strategy.

    SNDL Revenue & Expenses Breakdown as at Oct 2026
    SNDL Revenue & Expenses Breakdown as at Oct 2026

    Ardelyx (ARDX)

    Simply Wall St Financial Health Rating: ★★★★☆☆

    Overview: Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs in the United States and internationally, with a market cap of approximately $797.40 million.

    Operations: The company generates $450.89 million in revenue from the development and commercialization of biopharmaceutical products.

    Market Cap: $797.4M

    Ardelyx, Inc., with a market cap of approximately US$797.40 million, is navigating the complexities of the biopharmaceutical industry. Despite being unprofitable, Ardelyx has reduced its losses by 24.3% annually over five years and maintains a solid cash runway exceeding three years. Recent legal challenges have emerged due to claims of misleading investor communications impacting stock performance; the stock dropped from US$4.87 to US$4 after guidance revisions on IBSRELA and XPHOZAH revenues due to payer access issues. However, promising real-world data on IBSRELA's efficacy in reducing healthcare resource utilization offers potential for future growth amidst these hurdles.

    ARDX Financial Position Analysis as at Oct 2026
    ARDX Financial Position Analysis as at Oct 2026

    Applied Energetics (AERG)

    Simply Wall St Financial Health Rating: ★★★★☆☆

    Overview: Applied Energetics, Inc. develops, manufactures, and sells advanced high-performance lasers and optical systems, as well as integrated guided energy systems globally, with a market cap of $199.61 million.

    Operations: The company's revenue primarily comes from its Aerospace & Defense segment, totaling $0.24 million.

    Market Cap: $199.61M

    Applied Energetics, Inc., with a market cap of US$199.61 million, remains pre-revenue with sales of US$0.24 million primarily from its Aerospace & Defense segment. The company recently announced significant improvements in its ultrashort pulse laser technology, enhancing power and beam quality for potential defense applications. Despite these advancements, Applied Energetics faces financial challenges with less than a year of cash runway and ongoing losses totaling US$8.09 million for the first half of 2026. While short-term assets cover liabilities, high volatility and an inexperienced management team add to the investment risk profile typical for penny stocks.

    AERG Revenue & Expenses Breakdown as at Oct 2026
    AERG Revenue & Expenses Breakdown as at Oct 2026

    Summing It All Up

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.